A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy Participants

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: BMS-986165; Drug: Rabeprazole

Study type: Interventional

Funder types: Industry

Identifiers

NCT03979248

2019-001193-28 (EudraCT Number)

IM011-090

Details and patient eligibility

About

The purpose of this study is to evaluate the effects of stomach acid suppression by rabeprazole and BMS-986165 on how fast and complete the drug is absorbed into the body of healthy participants.

Enrollment: 21 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

• Healthy participant, as determined by medical history, physical examination, ECGs, and clinical laboratory determinations
• Body mass index of 18.0 kilogram per meter square (kg/m^2) to 32.0 kg/m^2
• Normal renal function at screening as evidenced by an estimated glomerular filtration rate (GFR) greater than (>) 80 milliliter per minute per 1.732 meter square (mL/min/1.732 m^2)

Exclusion Criteria:

• Any major surgery within 4 weeks of study drug administration
• Use of any prescription drugs or over-the-counter acid controllers
• Positive urine screen for drugs of abuse, alcohol, or cotinine
• History of allergy to BMS-986165, rabeprazole, or related compounds

Other protocol inclusion/exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Sequential Assignment

Masking: None (Open label)

---

21 participants in 1 patient group

BMS-986165 + Rabeprazole

Experimental group

Treatment:

Drug: Rabeprazole

Drug: BMS-986165